Key result
Rapidly evolving HF device therapies still lack robust evidence for newer technologies and specific indications.
Why the study?
Despite the rapid evolution of device therapy for heart failure, evidence remains lacking for newer technologies, common indications such as atrial fibrillation, and upgrading from previous devices.
Personalized medicine and rapid implementation of evolving device therapies and drugs are crucial for improving heart failure outcomes.
Answers are grounded in this paper and cite their sources.
Evidence gaps warrant caution before adopting newer HF devices; leaves open need for targeted RCTs on indications.
Device therapy for heart failure has rapidly evolved over 2 decades. The knowledge of indications, assessment lead and device technology has expanded to include CRT, leadless pacing and conduction system pacing such as His bundle and left bundle branch area pacing. But there is still a lack of evidence for these new technologies as well as for common indications such as atrial fibrillation and upgrading from a previous device. The role of personalized medicine will become increasingly important when selecting candidates for CRT, primary preventive ICD ablation procedures and emerging new devices such as cardiac contractility modulation (CCM). Rapidity of therapy is associated with outcome which will be a challenge. If properly implemented devices and drugs will have a large positive affect of HF outcomes.
No takes yet. Share an insight, caveat, or question.
Cecilia Linde (2023) conducted a review in Heart failure. Device therapy (CRT, leadless pacing, conduction system pacing, ICD, CCM) was evaluated. Device therapies for heart failure, including CRT and conduction system pacing, have rapidly evolved, but evidence remains lacking for newer technologies and specific indications.
Synapse has enriched 10 related papers. Consider them for comparative context: